Tracheobronchitis

Infectious tracheobronchitis, widely known as kennel cough, is one of the most common respiratory conditions affecting dogs worldwide. The term refers to inflammation of the trachea and bronchi caused by one or more infectious agents, and the condition is now more accurately described under the umbrella term canine infectious respiratory disease complex (CIRDC). This terminology reflects the understanding that the disease is not caused by a single pathogen but rather by a complex interplay of viral and bacterial agents that damage the respiratory epithelium and compromise local defense mechanisms.

The disease derives its colloquial name from its frequent occurrence in environments where dogs are housed together, such as boarding kennels, shelters, breeding facilities, and daycare centers. However, the name is somewhat misleading, as dogs can contract the disease in virtually any setting where they come into contact with infected animals or contaminated environments, including dog parks, veterinary waiting rooms, grooming facilities, training classes, and even casual encounters during walks. Any dog that interacts with other dogs or visits shared environments is potentially at risk.

Infectious tracheobronchitis is characterized by its hallmark clinical sign: a harsh, dry, paroxysmal cough that owners often describe as a honking or goose-like sound. The cough frequently concludes with a retching or gagging episode that can be mistaken for vomiting. While the disease is typically self-limiting in otherwise healthy adult dogs, resolving within one to three weeks without treatment, it can progress to serious and potentially life-threatening pneumonia in vulnerable populations including puppies, elderly dogs, immunocompromised individuals, and brachycephalic breeds with pre-existing airway compromise.

The economic and welfare impact of tracheobronchitis extends beyond individual patient care. Outbreaks in shelters and boarding facilities can necessitate quarantine measures, temporary closure, and intensive disinfection protocols that strain resources and disrupt operations. In breeding facilities, the disease can spread rapidly through the population and pose particular risks to neonatal puppies. Understanding the complex etiology, transmission dynamics, and management strategies for this condition is essential for veterinarians, shelter workers, kennel operators, and dog owners alike.

Infectious tracheobronchitis is a multifactorial disease caused by a variety of viral and bacterial pathogens that can act independently or, more commonly, in combination. The bacterial agent most closely associated with the disease is Bordetella bronchiseptica, a gram-negative aerobic coccobacillus that has a particular tropism for ciliated respiratory epithelium. Bordetella produces several virulence factors including adhesins that allow it to attach to respiratory cilia, toxins such as dermonecrotic toxin and tracheal cytotoxin that damage epithelial cells and impair mucociliary clearance, and mechanisms to evade host immune responses. While Bordetella can cause disease on its own, it more commonly acts as a secondary invader following initial viral damage to the respiratory tract.

Canine parainfluenza virus (CPIV) is one of the most common viral causes of tracheobronchitis. This enveloped RNA virus belongs to the paramyxovirus family and primarily infects the epithelial cells of the nasal passages, pharynx, trachea, and bronchi. Infection typically causes mild to moderate respiratory signs and predisposes the airways to secondary bacterial infection. Canine adenovirus type 2 (CAV-2) is another important viral contributor that targets the respiratory epithelium and can cause significant tracheobronchial inflammation. While CAV-2 is antigenically related to canine adenovirus type 1 (which causes infectious canine hepatitis), it preferentially affects the respiratory tract.

Canine respiratory coronavirus (CRCoV), distinct from the enteric canine coronavirus, emerged as a recognized respiratory pathogen in the early 2000s and has since been identified as a significant contributor to CIRDC worldwide. Canine herpesvirus (CHV-1) can cause respiratory signs, particularly in young puppies where it may produce severe systemic disease. Canine influenza virus, existing as both H3N8 and H3N2 subtypes, can cause respiratory illness ranging from mild cough to severe hemorrhagic pneumonia and has been responsible for notable outbreaks in various regions.

Mycoplasma species, particularly Mycoplasma cynos, are increasingly recognized as important respiratory pathogens in dogs that can cause or contribute to tracheobronchitis and pneumonia. Streptococcus equi subspecies zooepidemicus is an emerging pathogen associated with acute, rapidly progressive, and often fatal hemorrhagic pneumonia in shelter and group-housed dogs. The polymicrobial nature of CIRDC means that multiple pathogens are frequently detected simultaneously in affected dogs, and the clinical severity of disease is often greater with co-infections than with single-agent infections.

Environmental and host factors significantly influence susceptibility to infectious tracheobronchitis. Stress from transportation, rehoming, overcrowding, temperature extremes, and poor ventilation all compromise respiratory defenses and increase the likelihood of disease. Pre-existing conditions such as tracheal collapse, chronic bronchitis, or brachycephalic obstructive airway syndrome may predispose affected dogs to more severe clinical presentations.

The transmission of infectious tracheobronchitis occurs primarily through aerosolized respiratory secretions generated when infected dogs cough, sneeze, or bark. These respiratory droplets can contain large numbers of viral particles and bacteria that remain suspended in the air and can travel several meters, making airborne spread efficient in enclosed or poorly ventilated environments. The infectious dose for many of the causative agents is relatively low, meaning that even brief exposure to an actively coughing dog can result in transmission.

Direct contact between dogs, particularly nose-to-nose contact and mutual sniffing behaviors that are natural components of canine social interaction, provides another important route of transmission. Infected dogs shed pathogens in their nasal and oral secretions, and direct mucosal contact allows efficient transfer of organisms. Fomite transmission, in which pathogens are carried on contaminated objects such as shared water bowls, food dishes, toys, leashes, bedding, grooming equipment, and the hands and clothing of handlers, is also a significant route of spread, particularly in kennel and shelter environments.

The incubation period for infectious tracheobronchitis varies depending on the specific pathogen or combination of pathogens involved but generally ranges from two to fourteen days, with most dogs developing clinical signs within three to ten days of exposure. Importantly, dogs can begin shedding pathogens before they show clinical signs, creating a window during which apparently healthy dogs can transmit the disease to others. This pre-clinical shedding period makes isolation of infected individuals difficult and contributes to the explosive nature of outbreaks in group settings.

The duration of pathogen shedding extends beyond clinical recovery in many cases. Dogs recovering from Bordetella bronchiseptica infection may continue to shed the organism for six to fourteen weeks after resolution of clinical signs, even after antibiotic treatment. Viral shedding typically resolves more quickly, usually within one to two weeks for most respiratory viruses, but variability exists among individual dogs and specific pathogens. This prolonged shedding period has important implications for quarantine protocols and the timing of reintroduction of recovered dogs into group environments.

Environmental persistence of the causative organisms varies considerably. Bordetella bronchiseptica can survive on surfaces for extended periods under favorable conditions, though it is susceptible to most common disinfectants. Enveloped viruses such as parainfluenza and canine influenza are relatively fragile in the environment and are readily inactivated by disinfectants, desiccation, and ultraviolet light. Effective facility hygiene, including regular cleaning and disinfection of surfaces, equipment, and housing areas with appropriate products such as accelerated hydrogen peroxide or potassium peroxymonosulfate-based disinfectants, is essential for limiting environmental transmission.

The hallmark clinical sign of infectious tracheobronchitis is a distinctive, forceful, paroxysmal cough that is often described as dry, harsh, and honking in character. The cough can be remarkably intense and persistent, occurring in bouts that may last for several minutes and that are frequently triggered by excitement, exercise, pressure on the trachea (such as from a collar), changes in ambient temperature, or drinking water. Many dogs gag or retch at the end of a coughing episode, sometimes producing small amounts of white, foamy mucus that owners may mistake for vomit.

In uncomplicated cases, the cough is typically the most prominent and sometimes the only clinical sign. Affected dogs often remain bright, alert, and active between coughing episodes, maintaining normal appetite and energy levels. Body temperature may be normal or mildly elevated. A serous to mucopurulent nasal discharge may be present, and mild conjunctivitis or ocular discharge can accompany some viral infections. Tracheal sensitivity, demonstrated by a positive tracheal pinch test that elicits a cough when gentle pressure is applied to the trachea, is a consistent physical examination finding.

The clinical course of uncomplicated tracheobronchitis in otherwise healthy adult dogs typically follows a predictable pattern. The cough develops acutely, peaks in severity over the first few days, and gradually resolves over one to three weeks. However, some dogs experience a lingering cough that can persist for several weeks beyond the resolution of active infection, likely related to ongoing airway inflammation and hyper-reactivity. This prolonged cough can be frustrating for owners and may require symptomatic treatment even after the infectious process has resolved.

Complicated tracheobronchitis occurs when the infection progresses beyond the upper airways into the lower respiratory tract, resulting in bronchopneumonia. Signs of lower respiratory involvement include productive cough with purulent sputum, lethargy, decreased appetite, fever, increased respiratory rate and effort, exercise intolerance, and nasal discharge that becomes thick and mucopurulent or purulent. Dogs with pneumonia may exhibit crackles and increased bronchovesicular sounds on thoracic auscultation, and their general demeanor typically deteriorates noticeably compared to dogs with uncomplicated disease.

Certain populations are at heightened risk for complicated disease. Puppies younger than six months, particularly those that are incompletely vaccinated, may develop severe bronchopneumonia that can be fatal. Elderly dogs and those with concurrent chronic respiratory or systemic diseases are similarly vulnerable. Brachycephalic breeds such as Bulldogs, Pugs, and French Bulldogs may experience more severe clinical signs due to their compromised airway anatomy and reduced respiratory reserve. Immunocompromised dogs, including those receiving chemotherapy or immunosuppressive medications, are also at increased risk for progressive disease.

Diagnosis of infectious tracheobronchitis is frequently made on the basis of clinical presentation, history of exposure to other dogs, and physical examination findings, without requiring specific pathogen identification. The combination of an acute onset paroxysmal cough in a dog with recent exposure to other dogs, particularly in a kennel, shelter, or dog park setting, is highly suggestive of the diagnosis. Tracheal sensitivity on physical examination, an otherwise healthy-appearing dog between coughing episodes, and the absence of signs suggesting more serious lower respiratory disease support the clinical diagnosis.

Specific pathogen identification is not routinely necessary for individual pet dogs with uncomplicated disease but becomes important in outbreak situations, shelter settings, cases that fail to respond to standard treatment, and dogs with severe or complicated disease. Respiratory PCR panels have become the diagnostic tool of choice for pathogen identification and can simultaneously detect multiple viral and bacterial agents from a single sample. Specimens for PCR testing are typically collected as deep nasal swabs, pharyngeal swabs, or transtracheal wash or bronchoalveolar lavage samples, with the latter providing the most reliable sampling of the lower airways.

Bacterial culture and sensitivity testing of respiratory specimens can identify Bordetella bronchiseptica and other bacterial pathogens and provide antimicrobial susceptibility data to guide targeted antibiotic therapy. However, culture results must be interpreted carefully, as some organisms such as Bordetella and Mycoplasma can be found in the respiratory tract of clinically healthy dogs, and their presence does not necessarily confirm that they are the primary cause of disease. Correlation with clinical signs and the overall clinical picture is essential for accurate interpretation.

Thoracic radiography is not typically indicated for uncomplicated tracheobronchitis but should be performed in dogs with signs suggestive of lower respiratory involvement, dogs that fail to improve with appropriate treatment, and dogs with pre-existing cardiopulmonary conditions. Radiographic findings in uncomplicated disease are usually normal or show only mild bronchial or peribronchial patterns. In dogs with secondary pneumonia, radiographs may reveal alveolar infiltrates, lobar consolidation, or interstitial patterns typically affecting the cranioventral lung lobes.

Complete blood count and serum chemistry panels are generally unremarkable in uncomplicated tracheobronchitis. In dogs with pneumonia or systemic involvement, the blood count may show a neutrophilic leukocytosis with or without a left shift, and inflammatory markers may be elevated. These baseline laboratory values can help assess the severity of disease and guide treatment decisions. Arterial blood gas analysis or pulse oximetry should be performed in dogs with significant respiratory compromise to assess oxygenation status and guide the need for supplemental oxygen therapy.

Treatment of infectious tracheobronchitis is tailored to the severity of clinical signs and the presence or absence of complications. For uncomplicated cases in otherwise healthy adult dogs, the disease is self-limiting and may resolve without specific treatment. Supportive care, including rest, adequate hydration, and avoidance of irritants such as cigarette smoke, dust, and strong chemical fumes, forms the foundation of management. Using a harness instead of a collar helps minimize tracheal irritation that can trigger coughing episodes.

Cough suppressants may be prescribed for dogs with persistent, nonproductive coughs that interfere with rest and quality of life. Hydrocodone and butorphanol are the most commonly used antitussive agents in veterinary medicine and can provide significant relief from the distressing coughing paroxysms. Dextromethorphan, available in some over-the-counter formulations, may provide milder cough suppression but is generally less effective than prescription options. It is important to note that cough suppressants should be used with caution and are generally contraindicated in dogs with productive coughs or evidence of pneumonia, as suppressing the cough reflex can impair clearance of infected secretions from the lower airways.

Antibiotic therapy is not routinely indicated for uncomplicated viral tracheobronchitis in otherwise healthy adult dogs, as antibiotics do not affect viral pathogens and the disease typically resolves spontaneously. However, antibiotics are appropriate when Bordetella bronchiseptica infection is confirmed or strongly suspected, when secondary bacterial pneumonia has developed, when the patient is at high risk for complications, or when clinical signs are severe or not improving within the expected timeframe. Doxycycline is considered the first-line antibiotic for tracheobronchitis due to its activity against Bordetella, Mycoplasma, and many other respiratory bacterial pathogens, as well as its excellent penetration into respiratory secretions.

Alternative antibiotics include azithromycin, which offers the advantage of less frequent dosing and good respiratory tissue concentrations, and fluoroquinolones such as enrofloxacin or marbofloxacin for cases with confirmed resistant organisms or severe lower respiratory infection. Amoxicillin-clavulanate and trimethoprim-sulfonamide are additional options with activity against many respiratory pathogens. Nebulization with saline can help humidify the airways and facilitate clearance of respiratory secretions, and may be combined with nebulized antimicrobial agents in some treatment protocols.

Dogs with severe pneumonia require intensive management that may include hospitalization, intravenous fluid therapy, intravenous antibiotics, oxygen supplementation, bronchodilator therapy, nebulization and coupage, and nutritional support. These patients should be monitored closely with serial radiographs and bloodwork to assess treatment response. The prognosis for dogs with complicated pneumonia is generally good with appropriate treatment, though recovery may take several weeks and some dogs may develop chronic airway changes.

Vaccination represents the primary preventive measure against infectious tracheobronchitis, though it is important for dog owners to understand that available vaccines do not provide complete protection against all causative agents and cannot entirely eliminate the risk of disease. The Bordetella bronchiseptica vaccine is the most widely used and is available in three formulations: intranasal, oral, and injectable. Each formulation has distinct characteristics that influence its suitability for different situations.

Intranasal Bordetella vaccines are administered directly into the nostril and stimulate rapid local mucosal immunity in the respiratory tract, which is the primary site of pathogen entry. Protection can develop within forty-eight to seventy-two hours of administration, making this formulation particularly useful when rapid protection is needed, such as before boarding or in outbreak situations. Intranasal vaccines may cause mild transient sneezing or nasal discharge following administration. Oral Bordetella vaccines are administered into the cheek pouch and similarly stimulate mucosal immunity without the need for injection. Injectable Bordetella vaccines stimulate systemic humoral immunity and require approximately two weeks to develop protective antibody levels, making them less suitable for situations requiring rapid protection.

Core canine vaccines that provide protection against some respiratory pathogens include the distemper-parvovirus combination vaccines, which typically contain canine adenovirus type 2 (providing cross-protection against both CAV-1 and CAV-2) and canine parainfluenza virus components. These vaccines are administered as part of the standard puppy vaccination series and boosted throughout the dog's life. Canine influenza vaccines are available for both H3N8 and H3N2 strains and are recommended for dogs at high risk of exposure, such as those that frequently visit dog parks, attend group training, or stay at boarding facilities.

Beyond vaccination, environmental and management practices play crucial roles in preventing the spread of tracheobronchitis. Kennels, shelters, and boarding facilities should maintain adequate ventilation with a minimum of ten to fifteen air exchanges per hour, use appropriate disinfection protocols between occupants, minimize stress through appropriate housing and enrichment, and implement isolation procedures for dogs showing respiratory signs. All-in, all-out management protocols, where groups of dogs move through a facility together without mixing with new arrivals, can help limit transmission.

Individual dog owners can reduce their pet's risk by keeping vaccinations current, avoiding contact with dogs showing respiratory signs, choosing boarding and daycare facilities with documented vaccination requirements and good hygiene practices, and maintaining their dog's overall health through proper nutrition, regular veterinary care, and stress management. Dogs recovering from tracheobronchitis should be isolated from other dogs for a minimum of two weeks after resolution of clinical signs to prevent transmission during the prolonged shedding period.

Infectious tracheobronchitis does not show a strong breed predilection in the same way that genetic or conformational conditions do, as any dog can become infected when exposed to the causative pathogens. However, certain breeds and breed types are at increased risk for developing more severe disease or experiencing complications when they do contract the infection. Understanding these predispositions allows veterinarians and owners to implement more aggressive preventive measures and monitor susceptible dogs more closely during outbreaks.

Brachycephalic breeds represent the most clearly identifiable group at heightened risk for complicated tracheobronchitis. Breeds such as Bulldogs, French Bulldogs, Pugs, Boston Terriers, and Pekingese have inherently compromised airways due to their shortened skulls and the resulting anatomical abnormalities collectively known as brachycephalic obstructive airway syndrome (BOAS). These dogs have narrowed nostrils, elongated soft palates, everted laryngeal saccules, and hypoplastic tracheas that reduce their respiratory reserve and impair mucociliary clearance. When these dogs develop infectious tracheobronchitis, the additional inflammation and secretion production in already narrowed airways can lead to significant respiratory distress and a higher likelihood of progression to pneumonia.

Toy and miniature breeds, including Yorkshire Terriers, Chihuahuas, Pomeranians, and Toy Poodles, are often predisposed to tracheal collapse, a condition where weakened tracheal cartilage rings allow the trachea to flatten during respiration. Dogs with pre-existing tracheal collapse that develop tracheobronchitis may experience severe exacerbation of their cough and respiratory compromise. The inflammatory changes associated with the infection can worsen tracheal instability and lead to a more prolonged and severe clinical course.

Puppies of all breeds are at elevated risk due to their immature immune systems, particularly those that are incompletely vaccinated, recently weaned, or undergoing the stress of rehoming and transportation. Shelter and rescue puppies, who often face the combined challenges of incomplete vaccination, stress, crowding, and early-life nutritional deficiencies, represent one of the highest-risk populations for severe tracheobronchitis and secondary pneumonia.

Elderly dogs, regardless of breed, may experience more severe and prolonged disease due to age-related immune decline (immunosenescence), reduced mucociliary clearance, and the higher prevalence of concurrent chronic conditions such as congestive heart failure, chronic bronchitis, or neoplastic disease. Dogs receiving immunosuppressive therapies, including corticosteroids, cyclosporine, or chemotherapy agents, are also at increased risk for both acquiring infection and developing complications. Owners and veterinarians caring for dogs in any of these higher-risk categories should prioritize vaccination, minimize exposure to group settings during outbreak periods, and seek prompt veterinary attention at the first sign of respiratory illness.

The most significant complication of infectious tracheobronchitis is progression to bacterial bronchopneumonia, which occurs when infection extends from the upper airways into the lower respiratory tract and pulmonary parenchyma. This progression is more likely in immunocompromised dogs, puppies, geriatric patients, and dogs with pre-existing respiratory compromise. Bacterial pneumonia secondary to tracheobronchitis typically involves the cranioventral lung lobes and can be caused by Bordetella bronchiseptica, Streptococcus species, Pasteurella species, Escherichia coli, or other opportunistic bacteria that colonize the damaged respiratory epithelium.

Chronic bronchitis can develop as a sequel to severe or repeated episodes of infectious tracheobronchitis. Persistent airway inflammation leads to structural changes in the bronchial walls, including mucosal hyperplasia, goblet cell metaplasia, and smooth muscle hypertrophy, resulting in chronic cough, exercise intolerance, and progressive airway obstruction. Once established, chronic bronchitis requires lifelong management and may progressively worsen over time. Dogs that experience multiple episodes of tracheobronchitis may be at increased risk for developing this chronic condition.

Tracheal damage and irritation from severe or prolonged coughing episodes can exacerbate pre-existing tracheal collapse or contribute to the development of tracheal instability in predisposed breeds. The intense intratracheal pressure fluctuations generated during paroxysmal coughing can weaken already compromised tracheal cartilage, creating a self-perpetuating cycle where coughing worsens tracheal collapse, which in turn triggers more coughing. Managing this complication often requires a combination of antitussive therapy, anti-inflammatory medications, and environmental modifications.

In shelter and breeding facility settings, outbreaks of tracheobronchitis can be complicated by co-infections with more virulent pathogens. Streptococcus equi subspecies zooepidemicus has emerged as a particularly concerning pathogen in shelter dog populations, capable of causing acute, rapidly fatal hemorrhagic pneumonia. Canine distemper virus, while typically prevented by vaccination, can occasionally be identified in incompletely vaccinated populations and produces much more severe respiratory and systemic disease than the typical CIRDC pathogens.

The psychological impact of prolonged, severe coughing on both dogs and their owners should not be overlooked. Dogs experiencing intense coughing paroxysms may develop anxiety around triggers that provoke coughing, such as drinking water, excitement, or collar pressure. Owners may experience sleep disruption, stress, and concern about their dog's welfare during the often-extended course of the disease. Providing clear prognostic information, realistic expectations about the timeline for resolution, and symptomatic relief measures helps manage both the medical and emotional aspects of the condition.

Managing a dog during an active episode of tracheobronchitis requires patience, environmental modification, and consistent supportive care. The recovery period, which typically spans one to three weeks for uncomplicated cases, can feel prolonged for owners dealing with persistent coughing, particularly when it disrupts household routines and sleep. Understanding the expected clinical course and implementing practical management strategies can help both dogs and owners navigate the illness more comfortably.

Environmental modifications during recovery include maintaining adequate humidity in the home, which helps soothe irritated airways and facilitate clearance of respiratory secretions. Running a cool-mist humidifier in the room where the dog sleeps or allowing the dog to rest in a steamy bathroom for short periods can provide temporary relief from coughing. Air quality should be optimized by avoiding exposure to cigarette smoke, strong perfumes, household cleaning chemical fumes, dust, and other airborne irritants that can exacerbate airway inflammation and trigger coughing episodes.

Switching from a neck collar to a chest harness for the duration of the illness and beyond is an important practical measure. Pressure on the trachea from a collar consistently triggers coughing paroxysms in dogs with tracheobronchitis and can delay recovery. A well-fitted harness distributes pressure across the chest, avoiding tracheal compression entirely. For dogs that are prone to recurrent respiratory issues or have concurrent tracheal sensitivity, permanent transition to a harness may be advisable.

Isolation from other dogs is essential during the active phase of illness and for a minimum of two weeks after resolution of clinical signs. This means avoiding dog parks, boarding facilities, grooming appointments, daycare, training classes, and casual encounters with neighborhood dogs. Walking the dog during off-peak hours or in less-traveled areas can help minimize contact with other dogs while still providing gentle exercise and mental stimulation. Owners should inform their neighbors, dog walkers, and any other regular contacts that their dog is recovering from a contagious respiratory infection.

Long-term management considerations include maintaining current vaccination status, particularly for Bordetella and canine influenza in dogs with frequent social exposure. Dogs that experience recurrent episodes of tracheobronchitis should be evaluated for underlying conditions that may predispose them to repeated infections, such as tracheal collapse, chronic bronchitis, or immune deficiency. Building and maintaining a strong immune system through proper nutrition, regular exercise appropriate to the dog's condition, adequate rest, and stress management contributes to overall respiratory health and resilience against future infections.